Not checkedNot checked for notices yet.
FBXL2 counteracts Grp94 to destabilize EGFR and inhibit EGFR-driven NSCLC growth
Mengmeng Niu, Jing Xu, Yang Liu and 27 more
Nature Communications · 2021
doi:10.1038/s41467-021-26222-x (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
Aberrant EGFR activation is commonly found in non-small cell lung cancer (NSCLC). Here the authors show that E3 ubiquitin ligase FBXL2 targets EGFR and EGFR tyrosine kinase inhibitor (TKI)-resistant mutants for proteasome-mediated degradation to inhibit EGFR-driven NSCLC growth and TKI resistance.
Abstract licence: CC BY-NC-ND
Cited by papers we hold1
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.